Denali Therapeutics Inc. (DNLI) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $11.81M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $11.81M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $11.81M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 322.78M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 11.81M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Contract with Customer, Liability · Deferred Revenue · Contract with Customer, Liability, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | (m) | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | (m) | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability · Deferred Revenue · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability · Deferred Revenue · Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $32.11M |
| Finance lease obligations | $5.58M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.81M | (m) | (m) | (m) | $322.78M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $40.38M | (m) | (m) | (m) | $339.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $3.33M | (m) | (m) | (m) | $131.09M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.75M | (m) | (m) | (m) | $129.42M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $10.84M | (m) | (m) | (m) | $139.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $8.46M | (m) | (m) | (m) | $148.66M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $11.14M | (m) | (m) | (m) | $144.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $9.59M | (m) | (m) | (m) | $135.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $13.94M | (m) | (m) | (m) | $115.51M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.86M | (m) | (m) | (m) | $125.62M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $9.48M | $0.00 | $0.00 | $0.00 | $122.96M | (m) | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $118.45M | (m) | (m) | (m) | $379.00K | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $118.91M | (m) | (m) | (m) | $379.00K | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $442.64M | (m) | (m) | (m) | $379.00K | (m) |
| 2022-12-31 | (m) | $2.79M | $0.00 | $66.69M | $379.00K | $417.81M | (m) | $0.00 | $0.00 | $379.00K | $0.00 |
| 2022-09-30 | (m) | $7.54M | $23.00K | (m) | $379.00K | $416.30M | (m) | $23.00K | $0.00 | $379.00K | $0.00 |
| 2022-06-30 | (m) | $7.12M | $3.40M | (m) | $379.00K | $408.01M | (m) | $0.00 | $3.40M | $379.00K | $0.00 |
| 2022-03-31 | (m) | $3.36M | $3.40M | (m) | $379.00K | $402.93M | (m) | $0.00 | $3.40M | $379.00K | $0.00 |
| 2021-12-31 | (m) | $4.78M | $31.31M | $53.16M | $379.00K | $441.87M | (m) | $27.91M | $3.40M | $379.00K | $0.00 |
| 2021-09-30 | (m) | $4.82M | $32.64M | (m) | $701.00K | $437.69M | (m) | $1.32M | $31.31M | $701.00K | $0.00 |
| 2021-06-30 | (m) | $4.24M | $37.06M | (m) | $701.00K | $437.11M | (m) | $5.75M | $31.31M | $701.00K | $0.00 |
| 2021-03-31 | (m) | $1.63M | $44.21M | (m) | $701.00K | $442.50M | (m) | $12.89M | $31.32M | $701.00K | $0.00 |
| 2020-12-31 | (m) | $1.07M | $43.24M | $47.15M | $701.00K | $453.75M | (m) | $19.91M | $23.32M | $701.00K | $0.00 |
| 2020-09-30 | (m) | $2.81M | $44.57M | (m) | $379.00K | $187.76M | (m) | $28.02M | $16.56M | $379.00K | $0.00 |
| 2020-06-30 | (m) | $1.87M | $53.85M | (m) | $379.00K | $145.17M | (m) | $34.13M | $19.71M | $379.00K | $0.00 |
| 2020-03-31 | (m) | $2.32M | $59.42M | (m) | $379.00K | $150.55M | (m) | $24.67M | $34.75M | $379.00K | $0.00 |
| 2019-12-31 | (m) | $2.59M | $62.49M | $24.02M | $379.00K | $158.34M | (m) | $18.74M | $43.75M | $379.00K | $0.00 |
| 2019-09-30 | (m) | $2.02M | $65.98M | $3.48M | $386.00K | $164.78M | (m) | $18.18M | $47.80M | $386.00K | $0.00 |
| 2019-06-30 | (m) | $3.93M | $67.16M | $2.13M | $408.00K | $162.43M | (m) | $22.60M | $44.56M | $408.00K | $0.00 |
| 2019-03-31 | (m) | $3.66M | $68.00M | $1.11M | $440.00K | $159.95M | (m) | $23.15M | $44.85M | $440.00K | $0.00 |
| 2018-12-31 | (m) | $1.89M | $68.78M | $380.00K | $471.00K | $115.14M | (m) | $11.43M | $57.35M | $471.00K | $0.00 |
| 2018-09-30 | (m) | $3.35M | $57.11M | $138.00K | $124.00K | $83.30M | (m) | $12.66M | $44.45M | $124.00K | $0.00 |
| 2018-06-30 | (m) | $9.18M | $58.30M | $47.00K | $156.00K | $81.78M | (m) | $8.71M | $49.59M | $156.00K | $0.00 |
| 2018-03-31 | (m) | $1.38M | $59.95M | $63.00K | $188.00K | $74.92M | (m) | $8.43M | $51.52M | $188.00K | $0.00 |
| 2017-12-31 | (m) | $2.72M | $0.00 | $63.00K | (m) | $20.93M | (m) | (m) | (m) | $467.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |